Skip to main content

Peer Review reports

From: Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/ neu – positive advanced breast cancer: results of the CECOG LaVie trial

Original Submission
5 Apr 2015 Submitted Original manuscript
Author responded Author comments
Resubmission - Version 2
Submitted Manuscript version 2
Author responded Author comments
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Author responded Author comments
Resubmission - Version 4
Submitted Manuscript version 4
Author responded Author comments
Resubmission - Version 5
Submitted Manuscript version 5
Author responded Author comments
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
14 Feb 2016 Editorially accepted
18 Feb 2016 Article published 10.1186/s12885-016-2171-y

You can find further information about peer review here.

Back to article page